Needham analyst Mike Matson downgrades NeoGenomics (NASDAQ:NEO) from Buy to Hold.
Monopar Therapeutics Shelves Development Of Validive For Radiation Therapy-Related Complication
Monopar Therapeutics Inc (NASDAQ: MNPR) completed a pre-specified interim analysis for its Validive Phase 2b/3 VOICE trial for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy for oropharyngeal cancer (OPC).
